Migraine: cross-border specialty drug access for international patients
Neurology
ICD-10: G43
Quick orientation
Migraine affects approximately 1 billion people globally according to GBD estimates. Chronic migraine (15 or more headache days per month for 3 months) affects approximately 1 to 2 percent of adults.
Typical age of onset. Most commonly between adolescence and age 40. Female predominance is approximately 3 to 1 in adults.
Severity tiers. Severity ranges from infrequent episodic attacks to chronic migraine with substantial disability.
Why specialty drugs for Migraine are hard to access internationally
Multiple CGRP receptor antagonists and gepants have been FDA-approved over the past several years. Some have broad global registration; others are narrower. Patients with refractory migraine seeking newer agents often turn to cross-border supply.
Treatments approved by the FDA
- Nurtec ODT (rimegepant) — FDA approval: 2020. Mechanism: Oral CGRP receptor antagonist (acute and preventive). Route: Oral disintegrating tablet as needed or every other day. US WAC ballpark: Approximately USD 1,000 to 1,500 per month. Country pricing: UAE · Saudi Arabia · India · Egypt.
- Aimovig (erenumab) — FDA approval: 2018. Mechanism: CGRP receptor monoclonal antibody for migraine prevention. Route: Subcutaneous injection monthly. US WAC ballpark: Approximately USD 7,000 per year. Country pricing: UAE · Saudi Arabia · India · Egypt.
- Zavzpret (zavegepant) — FDA approval: 2023. Mechanism: Intranasal CGRP receptor antagonist for acute migraine. Route: Intranasal as needed. US WAC ballpark: Approximately USD 1,200 to 1,800 per month. Country pricing: Kuwait · Jordan · Bahrain.
- Ubrelvy (ubrogepant) — FDA approval: 2019. Mechanism: Oral CGRP receptor antagonist for acute migraine. Route: Oral as needed. US WAC ballpark: Approximately USD 1,000 to 1,500 per month. Country pricing: UAE · Saudi Arabia · India · Egypt.
Cross-border pathways used for Migraine
Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:
What your physician needs to know
- Confirm migraine diagnosis using ICHD-3 criteria.
- Document attack frequency, prior preventive therapy, and acute medication use.
- Screen for medication overuse headache.
- Neurologist co-management is recommended for refractory or chronic migraine.
- Counsel patients on appropriate acute versus preventive medication use.
Common questions
How do I choose between gepants and monoclonal antibodies?
Gepants are oral and can be used acutely or preventively; monoclonal antibodies are injectable preventive therapy. Choice depends on attack frequency, preferences, and prior response.
Are these drugs available locally?
Some are widely registered; others are narrower. We confirm by destination.
Can I use multiple migraine drugs?
Many patients use a preventive plus an acute medication. Your neurologist guides the combination.
How long does shipment take?
Five to ten business days from prescription receipt.
What documents are required?
Neurologist's prescription, headache diary, and prior treatment history.
Where Reserve Meds fits in
Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Migraine, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.
We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.
Start a request
Reserved for you.